View Clinical Trial (Medical Research Study)

Effect of Rosuvastatin on Cardiovascular Risk in HIV-Infected Individuals With Low High Density Lipoprotein (HDL) Cholesterol - NCT00986999-96816(Clinical Trial 353182)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Honolulu
State:  
HI
Zip Code: 96816
Conditions: HIV Infections - Cardiovascular Disease
Purpose: Rosuvastatin belongs to a class of medications commonly called "statins" which are medications given for high low density lipoprotein (LDL) 'bad' cholesterol to prevent atherosclerosis (hardening of blood vessels) and lower risk of heart attacks and other circulation problems. Recent studies in the general non-HIV infected population have shown that the beneficial effect of statins in preventing circulation problems is larger than would be expected from lowering of LDL-cholesterol alone. It has been suggested that the additional beneficial effect of statins may be due to the anti-inflammatory effect of statins. The risk of heart attacks and other circulation problems may be high in HIV infected individuals. This may be due to the inflammatory stress effects of HIV. The main purpose of the study is to see if rosuvastatin will have a beneficial effect on the circulatory system in HIV infected individuals even in those who do not have high LDL cholesterol levels. Therefore, in HIV-infected individuals with normal or low LDL cholesterol levels but with evidence of low HDL cholesterol levels which may be a sign of low grade inflammation, the study will look at whether 6 months of rosuvastatin will lead to improvement in brachial artery flow-mediated dilatation (FMD), a marker of early atherosclerosis (hardening of the blood vessels).
Study summary:
Criteria: Inclusion Criteria: - HIV infection - Age > 40 years old - On stable antiretroviral therapy for > 6 months with no plans to change therapy during the randomized treatment phase of the study - Plasma HIV RNA < 50 copies/mL - Karnofsky performance score > 70 within 30 days prior to study entry - Ability to understand and sign informed consent - Following laboratory values obtained within 30 days prior to randomization: - Absolute neutrophil count (ANC) > 750/mm3 - Hemoglobin > 8.0 g/dL - Platelets > 50,000/mm3 - ALT (SGPT) and AST (SGOT) < 2.5 x ULN - Fasting glucose < 126 mg/dL - TSH < 3.0 mIU/L - HDL-C < 40 mg/dL in men, < 50 mg/dL in women - Direct LDL-C < 130 mg/dL - Calculated creatinine clearance > 50 mL/min - Willing to be treated with rosuvastatin or be on an observational arm for a minimum of 6 months - Female subject must not participate in a conception process (active attempt to become pregnant) or be post-menopausal. If participating in sexual activity that could lead to pregnancy, the subject must use contraception while receiving study medication and 30 days after stopping the medication Exclusion criteria - History of past cardiovascular event - Acute illnesses or active AIDS-defining opportunistic infection (OI) within 30 days prior to entry - Other chronic illness including diabetes, autoimmune diseases, and endocrinopathies - Serology positive for hepatitis B surface antigen or hepatitis C antibody - Signs and symptoms of liver failure - Receipt of supraphysiologic glucocorticoid therapy within 3 months prior to study entry - Use of lipid lowering agents within 30 days prior to study entry - Receipt of an HIV vaccine or investigational agents - Pregnancy or breast-feeding - Presence of any active malignancy within the last 5 years - Severe Hypertension (Systolic >/= 180 or Diastolic >/= 110 mm Hg) - Use of oral postmenopausal hormone replacement therapy - Known hypersensitivity to rosuvastatin - Active drug or alcohol dependence - Any acute illness within 30 days prior to study entry that, in the opinion of the site investigator, would interfere with participation in the study. - Use of lopinavir/ritonavir (Kaletra) as part of current HIV antiretroviral regimen
Study is available at: Hawaii Center for AIDS
Honolulu, HI 96816
United States

Primary Contact:
Lorna Nagamine, RN
Phone: 808-737-2751

Secondary Contact:
Lorna Nagamine, RN
Phone: 808 737-2751
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.